Evidence map›Paper›PMID 40596538›Full record

ArticleScientific reports2025

Enhanced therapeutic efficacy of silibinin loaded silica coated magnetic nanocomposites against Pseudomonas aeruginosa in Combination with Ciprofloxacin and HepG2 cancer cells.

Sanaz Borji, Mahdi Shahriarinour, Shahab Shariati, Najmeh Ranji, Mohammad Nikpassand

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Preparation of silibinin- dendrimer-stabilized Au nanoparticles for decreasing vancomycin resistance in S. aureus clinical isolates.International microbiology : the official journal of the Spanish Society for Microbiology · 2026
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sanaz BorjiDepartment of Biology, Ra.C., Islamic Azad University, Rasht, P.O. Box: 3516-41335, Iran.
Mahdi ShahriarinourDepartment of Biology, Ra.C., Islamic Azad University, Rasht, P.O. Box: 3516-41335, Iran. ma.shahriarinour@iau.ac.ir.
Shahab ShariatiDepartment of Chemistry, Ra.C., Islamic Azad University, Rasht, Iran.
Najmeh RanjiDepartment of Biology, Ra.C., Islamic Azad University, Rasht, P.O. Box: 3516-41335, Iran.
Mohammad NikpassandDepartment of Chemistry, Ra.C., Islamic Azad University, Rasht, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Silibinin, a major bioactive compound extracted from Silybum marianum, possesses notable antioxidant, antitumor, hepatoprotective, and antibacterial activities. However, its poor solubility limits its clinical applications. This study aimed to enhance the delivery of silibinin by synthesizing magnetic nanocomposites (MNCs) and evaluating their efficacy against clinical isolates of Pseudomonas aeruginosa and HepG2 cancer cells. The physicochemical properties of the Fe

Indexed as

Anti-Bacterial AgentsCiprofloxacinNanocompositesPseudomonas aeruginosaSilybinAntineoplastic AgentsBiofilmsHep G2 CellsHumansMicrobial Sensitivity TestsSilicon DioxideAnti-Bacterial AgentsAntineoplastic AgentsCiprofloxacinSilicon DioxideSilybinApoptosisFe3O4@SiPrHepG2 cellsPseudomonas aeruginosaSilibinin

Identifiers

PMID40596538
PMCPMC12217157

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.